609 related articles for article (PubMed ID: 19457065)
41. A potential role for zinc alterations in the pathogenesis of Alzheimer's disease.
Lyubartseva G; Lovell MA
Biofactors; 2012; 38(2):98-106. PubMed ID: 22447723
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.
Bürger S; Noack M; Kirazov LP; Kirazov EP; Naydenov CL; Kouznetsova E; Yafai Y; Schliebs R
Int J Dev Neurosci; 2009 Oct; 27(6):517-23. PubMed ID: 19589380
[TBL] [Abstract][Full Text] [Related]
43. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
Baig AM
ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
[TBL] [Abstract][Full Text] [Related]
44. Vaccines: chasing the dream.
Schnabel J
Nature; 2011 Jul; 475(7355):S18-9. PubMed ID: 21760578
[No Abstract] [Full Text] [Related]
45. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
[TBL] [Abstract][Full Text] [Related]
46. [Problems of the amyloid beta precursor protein in pathogenesis of the Alzheimer type dementia].
Shoji M; Hirai S
Nihon Ronen Igakkai Zasshi; 1996 Mar; 33(3):164-8. PubMed ID: 8648890
[No Abstract] [Full Text] [Related]
47. Molecular and cellular biology of Alzheimer amyloid.
Marotta CA; Majocha RE; Tate B
J Mol Neurosci; 1992; 3(3):111-25. PubMed ID: 1627458
[TBL] [Abstract][Full Text] [Related]
48. Protective roles of melatonin against the amyloid-dependent development of Alzheimer's disease: A critical review.
Vincent B
Pharmacol Res; 2018 Aug; 134():223-237. PubMed ID: 29981776
[TBL] [Abstract][Full Text] [Related]
49. Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation.
Sola Vigo F; Kedikian G; Heredia L; Heredia F; Añel AD; Rosa AL; Lorenzo A
Neurobiol Aging; 2009 Sep; 30(9):1379-92. PubMed ID: 18187234
[TBL] [Abstract][Full Text] [Related]
50. Small things matter: Implications of APP intracellular domain AICD nuclear signaling in the progression and pathogenesis of Alzheimer's disease.
Bukhari H; Glotzbach A; Kolbe K; Leonhardt G; Loosse C; Müller T
Prog Neurobiol; 2017 Sep; 156():189-213. PubMed ID: 28587768
[TBL] [Abstract][Full Text] [Related]
51. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!
Lee HG; Zhu X; Nunomura A; Perry G; Smith MA
Am J Pathol; 2006 Sep; 169(3):738-9. PubMed ID: 16936250
[No Abstract] [Full Text] [Related]
52. N-truncated Aβ
Wirths O; Walter S; Kraus I; Klafki HW; Stazi M; Oberstein TJ; Ghiso J; Wiltfang J; Bayer TA; Weggen S
Alzheimers Res Ther; 2017 Oct; 9(1):80. PubMed ID: 28978359
[TBL] [Abstract][Full Text] [Related]
53. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein?
Neve RL; McPhie DL; Chen Y
Biochem Soc Symp; 2001; (67):37-50. PubMed ID: 11447838
[TBL] [Abstract][Full Text] [Related]
54. Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease.
Rojas-Fernandez CH; Chen M; Fernandez HL
Pharmacotherapy; 2002 Dec; 22(12):1547-63. PubMed ID: 12495166
[TBL] [Abstract][Full Text] [Related]
55. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
Adlard PA; James SA; Bush AI; Masters CL
Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
[TBL] [Abstract][Full Text] [Related]
56. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.
Karran E; Mercken M; De Strooper B
Nat Rev Drug Discov; 2011 Aug; 10(9):698-712. PubMed ID: 21852788
[TBL] [Abstract][Full Text] [Related]
57. [Therapeutic strategy by manipulating some protease activities for Alzheimer's disease].
Iwata N; Higuchi M; Saido TC
Nihon Yakurigaku Zasshi; 2008 May; 131(5):320-5. PubMed ID: 18480559
[No Abstract] [Full Text] [Related]
58. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
59. Review of drugs for Alzheimer's disease.
Sun X; Jin L; Ling P
Drug Discov Ther; 2012 Dec; 6(6):285-90. PubMed ID: 23337815
[TBL] [Abstract][Full Text] [Related]
60. Beta-sheet breakers for Alzheimer's disease therapy.
Bieler S; Soto C
Curr Drug Targets; 2004 Aug; 5(6):553-8. PubMed ID: 15270201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
